Empresa Opexa Therapeutics Inc Nasdaq
Acciones
US68372T3014
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 17/11 |
Tanya Hayden
COO | Chief Operating Officer | 44 | 01/06/21 |
John M. Klopp
CTO | Chief Tech/Sci/R&D Officer | 50 | - |
Jim DeNike
IRC | Investor Relations Contact | - | - |
Bernie Paul
HRO | Human Resources Officer | 65 | 01/05/19 |
Renee Carroll
LAW | General Counsel | - | 01/01/20 |
Jason Kneeland
AUD | Comptroller/Controller/Auditor | - | 01/11/17 |
Kim Tharaldsen
SAM | Sales & Marketing | - | 05/02/18 |
Corporate Officer/Principal | 57 | 01/12/13 | |
Donald Joseph
LAW | General Counsel | 70 | 01/04/18 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 17/11 |
Joshua Schafer
BRD | Director/Board Member | 53 | 17/11 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 24 463 726 | 24 463 726 ( 100,00 %) | 0 | 100,00 % |
Información de la empresa
![Dirección Opexa Therapeutics Inc](https://cdn.zonebourse.com/static/address/24007935.png)
Sector
Varia. 1 de ene. | Capi. | |
---|---|---|
+20,17 % | 126 mil M | |
+24,67 % | 118 mil M | |
+24,40 % | 27,87 mil M | |
-17,74 % | 20,95 mil M | |
-15,73 % | 16,92 mil M | |
-15,21 % | 16,18 mil M | |
+11,91 % | 14,84 mil M | |
-47,10 % | 14,79 mil M | |
+54,50 % | 14,08 mil M |